Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders

Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders

In pediatric patients, the selective serotonin reuptake inhibitors (SSRIs) escitalopram and citalopram (es/citalopram) are commonly prescribed for anxiety and depressive disorders. However, pharmacogenetic studies examining CYP2C19 metabolizer status and es/citalopram treatment outcomes have largely...

Full description

Bibliographic Details
Main Authors: Stacey L. Aldrich, Ethan A. Poweleit, Cynthia A. Prows, Lisa J. Martin, Jeffrey R. Strawn, Laura B. Ramsey
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-02-01
Series:Frontiers in Pharmacology
Subjects:
pharmacogenetics
CYP2C19
SSRI (selective serotonin reuptake inhibitor)
antidepressant
anxiety disorders
depressive disorder
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00099/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.00099/full

Similar Items